The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGRA.L Regulatory News (GRA)

  • There is currently no data for GRA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pre-close statement and Trading Update

6 Apr 2022 12:00

RNS Number : 4973H
Grafenia plc
06 April 2022
 

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation. With the publication of this announcement, this information is now considered to be in the public domain.

6 April 2022

Grafenia plc

("Grafenia" or "the Company" or the "Group")

 

Pre-close statement and Trading Update

 

Since our last update on 22 November 2021, sales have continued to improve. Each month has traded better than the previous year, as each round of restrictions has been lifted.

 

In December and January, there was uncertainty about whether restrictions would be reintroduced. Some exhibitions and events were postponed, affecting business confidence. March saw a significant bounce back. Many of those events have returned or been rescheduled for the summer. Total sales in March were the highest recorded since November 2019, before the pandemic.

 

We expect to end the full year with sales in excess of £12.0m (2021: £9.65m). Whilst this isn't back to pre-pandemic levels, our cost base is significantly different and our breakeven point is much lower. We generated positive EBITDA in 8 of 12 months this year. After negative EBITDA in 2021, we expect full year 2022 EBITDA to be positive and to have a smaller loss before tax than the previous year. Cash at 31 March 2022 was £1.5m (2021: £2.7m).

 

However, like most businesses, we have faced cost rises across the board. Paper has increased by 30-50%, due to distribution costs, shortages and energy. We have increased our prices three times in 2022 to reflect this. Fuel and energy prices remain at high levels and are not helped by global events. This situation impacts everyone. We continue to track competitor pricing and nobody is immune to these pressures.

 

Our partner network has remained stable in what have been turbulent times. It's always sad to lose partners, but compared to the sector at large, our network has proved resilient. We have continued to add new Nettl partners in the UK and US. At the year end, we had 220 Nettl partners (2021: 232) around the world. Partners often tell us that being part of our network has helped navigate these difficult times. The board would like to thank our partners and acknowledge their stamina and efforts.

 

Each of our business units performed better than last year. In particular, our company stores continue to progress. We expect sales to be up by 40% at approximately £2.56m (2021: £1.83m). In the second half of 2020, we rolled three businesses into our Birmingham and Dublin company stores. If we exclude them this year, we expect like-for-like sales to be up 20%.

 

The pandemic caused many businesses to reflect on what the future should look like. For us, we used the time to invest in our platform. We have been working on a digital transformation programme to improve the sign and install industry.

 

We successfully launched our "WorksThing" app at the Sign & Digital exhibition in March. Optimised for the signage sector, WorksThing.com is a complete workflow tool for managing signage installations, from start to finish. It's Software-as-a-Service, like Nettl. Sign businesses pay a monthly subscription, from £49 per user per month. Their installers can connect their calendars to provide online booking, like reserving a table at a restaurant. Each install is mapped on a live timeline, so everyone can keep track of progress. A modern chat messaging system connects clients with studios, production and install crews.

 

It's early days, but multiple businesses have signed up for a free trial and we're pleased with the reaction at the event. We expect that some WorksThing clients will become Nettl partners, as they seek to get more from every client relationship with the Nettl toolkit.

 

Outlook

We're cautiously optimistic about the upcoming year. We remain focussed on achieving our mid-term goal of 10-15% EBITDA. Our search for software businesses continues. We hope to update the market with more detailed progress shortly.

 

For further information:

 

Grafenia plc

Peter Gunning (CEO) 07973 191 632

 

Allenby Capital Limited (Nominated Adviser and Broker)

David Hart / Liz Kirchner (Corporate Finance) 0203 328 5656

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTIFMMTMTAMBLT
Date   Source Headline
17th Oct 20237:00 amRNSChange of Company name effective
16th Oct 20236:30 pmRNSDirector/PDMR Shareholding
6th Oct 20239:37 amRNSGrant of options
26th Sep 202312:21 pmRNSResult of AGM and Change of Name and Website
21st Sep 20237:00 amRNSHolding(s) in Company
20th Sep 20235:39 pmRNSHolding(s) in Company
15th Sep 20235:47 pmRNSReplacement: Result of GM and Open Offer
15th Sep 202310:22 amRNSResult of General Meeting and Open Offer
8th Sep 20232:03 pmRNSDirector/PDMR Shareholding
29th Aug 20237:00 amRNSFundraise of up to £27.9 million and other matters
26th Jul 20237:00 amRNSFinal Results
1st Jun 20237:00 amRNSUpdate re. the sale of Works Manchester Limited
3rd May 20237:00 amRNSPre-close statement and Trading Update
3rd Apr 20231:13 pmRNSHolding(s) in Company
17th Feb 202312:35 pmRNSAcquisition of Topfloor Systems Limited
20th Jan 20232:49 pmRNSBond Issue
18th Jan 20237:00 amRNSAcquisition of Care Management Systems Limited
28th Dec 20227:00 amRNSHolding(s) in Company
13th Dec 20227:00 amRNSReplacement: Bond Issue
12th Dec 20225:51 pmRNSBond Issue
7th Dec 20225:07 pmRNSAcquisition of Watermark Technologies Limited
24th Nov 20227:00 amRNSHalf-year Report
31st Oct 20227:00 amRNSBoard Appointment
7th Oct 202211:37 amRNSHolding(s) in Company
6th Oct 20221:48 pmRNSHolding(s) in Company
27th Sep 202212:56 pmRNSBond Issue
22nd Sep 20224:09 pmRNSAcquisition of Vertical Plus Limited
14th Sep 20222:18 pmRNSResult of AGM
27th Jul 20223:18 pmRNSReplacement: Final Results
27th Jul 20227:00 amRNSFinal Results
19th May 20227:00 amRNSSale of Subsidiary and Board Changes
4th May 20229:01 amRNSDirector/PDMR Shareholding
6th Apr 202212:00 pmRNSPre-close statement and Trading Update
22nd Nov 20217:00 amRNSHalf-year Report
15th Sep 202110:35 amRNSResult of AGM
15th Sep 20217:00 amRNSAGM Trading Statement
28th Jul 20217:00 amRNSFinal Results
16th Apr 20217:00 amRNSPre-close Trading and Strategy Update
3rd Mar 20217:00 amRNSBlock admission review & block cancellation
8th Jan 202112:38 pmRNSStmnt re Share Price Movement
31st Dec 20201:00 pmRNSTotal Voting Rights
14th Dec 20203:45 pmRNSIssue of Equity re Share Stake Scheme
25th Nov 20207:00 amRNSHalf-year Report
22nd Sep 202011:31 amRNSResult of AGM
22nd Sep 20207:00 amRNSAGM Trading Statement and Acquisition Update
3rd Sep 20207:00 amRNSBlock listing Interim Review
1st Sep 20207:00 amRNSReplacement: Final Results
12th Aug 20207:00 amRNSFinal Results
24th Jul 202012:37 pmRNSReplacement: Bond Facility & trading update
15th Jul 202010:45 amRNSBond Facility for up to £50m & trading update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.